Harvard Bioscience (HBIO) Resumen de Acciones
Harvard Bioscience, Inc. desarrolla, fabrica y vende tecnologías, productos y servicios para aplicaciones de ciencias de la vida en América, Europa, Oriente Medio, África, Asia y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
HBIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Harvard Bioscience, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$8.03 |
| Máximo en las últimas 52 semanas | US$9.40 |
| Mínimo de 52 semanas | US$3.76 |
| Beta | 1.53 |
| Cambio en 1 mes | 20.66% |
| Variación en 3 meses | 34.06% |
| Cambio de 1 año | 81.84% |
| Variación en 3 años | -82.35% |
| Variación en 5 años | -89.52% |
| Variación desde la OPV | -92.35% |
Noticias y actualizaciones recientes
HBIO: Profitability And Cash Flow Improvements Will Support Higher Future Multiple
Analysts have raised the Harvard Bioscience price target to $7.50 from $6. This reflects their view that recent profitability and cash flow efforts could support a higher future P/E multiple.HBIO: Reverse Split And 2026 Execution Risks Will Pressure Overvalued Shares
Analysts have lifted their price target on Harvard Bioscience to $6.00, primarily reflecting the updated modeling of the recent 1-for-10 reverse stock split. What's in the News Harvard Bioscience issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.5 million to US$22.5 million.Recent updates
HBIO: Profitability And Cash Flow Improvements Will Support Higher Future Multiple
Analysts have raised the Harvard Bioscience price target to $7.50 from $6. This reflects their view that recent profitability and cash flow efforts could support a higher future P/E multiple.HBIO: Reverse Split And 2026 Execution Risks Will Pressure Overvalued Shares
Analysts have lifted their price target on Harvard Bioscience to $6.00, primarily reflecting the updated modeling of the recent 1-for-10 reverse stock split. What's in the News Harvard Bioscience issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.5 million to US$22.5 million.HBIO: Reverse Split And 2026 Execution Uncertainty Will Shape Balanced Outlook
Analysts have updated their models for Harvard Bioscience following the 1:10 reverse split, lifting the stated price target from $0.60 to $6 as they align their valuation work with the new share count and revised long term assumptions on growth, margins and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts are treating the 1:10 reverse split as a housekeeping move that aligns the share price, share count and stated price target.When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it led the NASDAQCM gainers with a...HBIO: Reverse Split And 2026 Outlook Will Frame Balanced Risk Reward
Narrative Update: Harvard Bioscience Analysts have reset Harvard Bioscience's price target to $6.00 from $0.60, aligning with the recent 1:10 reverse split and updated revenue expectations for 2026. Analyst Commentary Recent commentary around Harvard Bioscience focuses on how the reverse split and updated 2026 revenue expectations feed into valuation and execution risk.HBIO: Reverse Split And Cost Savings Plan Will Support Future Upside Potential
Narrative Update Analysts have reset their price target on Harvard Bioscience to $6, largely reflecting the recent 1:10 reverse split and the updated revenue expectations in their models. Analyst Commentary Recent research updates on Harvard Bioscience focus on the technical impact of the 1:10 reverse split and revised revenue assumptions, rather than any major shift in the underlying story.HBIO: Reverse Split And Cost Savings Program Will Support Future Recovery Potential
Analysts have reset their price target for Harvard Bioscience from $0.60 to $6.00, reflecting the recent 1 for 10 reverse split and updated modeling rather than a change in the underlying view on the business. Analyst Commentary Recent research updates on Harvard Bioscience have focused on recalibrating models and targets to reflect the 1 for 10 reverse split and revised revenue expectations, rather than a wholesale change in long term conviction.HBIO: Reset Expectations And Manufacturing Shift Will Set Up Recovery Potential
Analysts have cut their price target on Harvard Bioscience from $2.00 to $0.60, citing a reduced 2026 revenue estimate of $89.2m versus $95.6m previously and stating that the timing of any recovery is still hard to pinpoint. Analyst Commentary Recent commentary around Harvard Bioscience is focused squarely on the reset to expectations and what it could imply for the share price and business execution over the next few years.Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce
Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares have continued their recent momentum with a 27% gain in the last month...Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive Enough
Harvard Bioscience, Inc.'s ( NASDAQ:HBIO ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy...Demographic Shifts And NIH Funding Will Unlock Biomedical Potential
Analysts have lowered Harvard Bioscience’s price target from $3.00 to $2.00 due to increased uncertainty around research funding, drug pricing pressures, tariff risks, and a generally more cautious sector outlook. Analyst Commentary Uncertainty surrounding basic research funding potentially impacting sector performance.Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target
NasdaqGM:HBIO 1 Year Share Price vs Fair Value Explore Harvard Bioscience's Fair Values from the Community and select...Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% Pounding
To the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 26% in...Expanding SoHo, BTX, And Mesh MEA Will Open New Markets
Expansion of SoHo platform and BTX systems could drive revenue growth in industrial and academic markets through broader applications and bioproduction processes.Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), might not be a large cap stock, but it saw significant share price movement...Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop
To the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 49% in...Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price Plunge
Unfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it saw a significant share price...Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Harvard Bioscience, Inc. ( NASDAQ:HBIO ) is...Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
The Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has done very well over the last month, posting an excellent...Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.55 Current...Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has fared very poorly over the last month, falling by a...An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.84 Harvard...Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Rentabilidad de los accionistas
| HBIO | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 0.1% | -1.9% | -0.9% |
| 1Y | 81.8% | 25.2% | 14.2% |
Rentabilidad vs. Industria: HBIO superó a la industria US Life Sciences, que obtuvo un rendimiento del 25.2% el año pasado.
Rentabilidad vs. Mercado: HBIO superó al mercado US, que obtuvo un rendimiento del 14.2% el año pasado.
Volatilidad de los precios
| HBIO volatility | |
|---|---|
| HBIO Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: HBIO no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HBIO ha disminuido de 13% a 6% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1901 | 328 | John Duke | www.harvardbioscience.com |
Harvard Bioscience, Inc. desarrolla, fabrica y vende tecnologías, productos y servicios para aplicaciones de ciencias de la vida en América, Europa, Oriente Medio, África, Asia e internacionalmente. La empresa ofrece productos de tecnología celular y molecular, como jeringuillas y bombas de infusión peristálticas; instrumentos de electroporación y electrofusión, analizadores de aminoácidos, espectrofotómetros y otros equipos para pruebas e investigación a nivel molecular; e instrumentación y equipos de medición científica de precisión, incluidos sistemas de adquisición de datos para análisis celular, soluciones completas de microconjuntos de electrodos para registros in vivo y sistemas in vitro para registros extracelulares. Ofrece productos preclínicos que incluyen plataformas para evaluar datos fisiológicos de organismos con fines de investigación, descubrimiento de fármacos y servicios de desarrollo de fármacos que comprenden sistemas de telemetría implantables y de uso externo en investigación para recopilar datos cardiovasculares, del sistema nervioso central, respiratorios y metabólicos; productos conductuales; productos quirúrgicos y de órganos aislados, instrumentos y accesorios para la investigación de tejidos y órganos en laboratorio, incluidos productos quirúrgicos, sistemas de infusión y sistemas de investigación del comportamiento; soluciones de sistemas respiratorios llave en mano, incluidas cámaras pletismográficas, hardware de adquisición de datos, software de análisis de señales fisiológicas y generación de informes finales; sistemas de inhalación y exposición; y sistemas de adquisición y análisis de datos aptos para BPL.
Resumen de fundamentos de Harvard Bioscience, Inc.
| Estadísticas fundamentales de HBIO | |
|---|---|
| Capitalización bursátil | US$36.56m |
| Beneficios(TTM) | -US$10.41m |
| Ingresos (TTM) | US$87.81m |
¿Está HBIO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HBIO | |
|---|---|
| Ingresos | US$87.81m |
| Coste de los ingresos | US$36.74m |
| Beneficio bruto | US$51.07m |
| Otros gastos | US$61.48m |
| Beneficios | -US$10.41m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.29 |
| Margen bruto | 58.16% |
| Margen de beneficio neto | -11.86% |
| Ratio deuda/patrimonio | 494.5% |
¿Cómo se ha desempeñado HBIO a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/13 05:25 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Harvard Bioscience, Inc. está cubierta por 6 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Paul Knight | KeyBanc Capital Markets Inc. |
| Timothy Chiang | Northland Capital Markets |